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Abstract
Background: Clinical studies in children are necessary yet conducting multiple visits at study centers remains
challenging. The success of “care-at-home” initiatives and remote clinical trials suggests their potential to facilitate
conduct of pediatric studies. This pilot aimed to study the feasibility of remotely collecting valid (i.e. complete and
correct) saliva samples and clinical data utilizing mobile technology.
Methods: Single-center, prospective pilot study in children undergoing elective tonsillectomy at the University of
Basel Children’s Hospital. Data on pain scores and concomitant medication and saliva samples were collected by
caregivers on two to four inpatient study days and on three consecutive study days at home. A tailored mobile
application developed for this study supported data collection. The primary endpoint was the proportion of
complete and correct caregiver-collected data (pain scale) and saliva samples in the at-home setting. Secondary
endpoints included the proportion of complete and correct saliva samples in the inpatient setting, subjective
feasibility for caregivers, and study cost.
Results: A total number of 23 children were included in the study of which 17 children, median age 6.0 years
(IQR 5.0, 7.4), completed the study. During the at-home phase, 71.9% [CI = 64.4, 78.6] of all caregiver-collected pain
assessments and 53.9% [CI = 44.2, 63.4] of all saliva samples were complete and correct. Overall, 64.7% [CI = 58.7, 70.4]
of all data collected by caregivers at home was complete and correct. The predominant reason for incorrectness of
data was adherence to the timing of predefined patient actions. Participating caregivers reported high levels of
satisfaction and willingness to participate in similar trials in the future. Study costs for a potential sample size of 100
patients were calculated to be 20% lower for the at-home than for a traditional in-patient study setting.
Conclusions: Mobile device supported studies conducted at home may provide a cost-effective approach to facilitate
conduct of clinical studies in children. Given findings in this pilot study, data collection at home may focus on
electronic data capture rather than biological sampling.
Keywords: Remote studies, Mobile studies, Pediatrics, Data validity, Data quality, Feasibility
* Correspondence: belinda.vonniederhausern@usb.ch
1Clinical Trial Unit, Department of Clinical Research, University and University
Hospital of Basel, Schanzenstrasse 55, 4031 Basel, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
von Niederhäusern et al. BMC Medical Research Methodology  (2017) 17:163 
DOI 10.1186/s12874-017-0438-x
Background
High quality research relies on the collection of high qual-
ity data. Traditionally, this is done in the inpatient setting
or through ambulatory visits to a study site, which can
present a barrier to participation (e.g. cost, travel burden,
time) and a risk to the validity of research (e.g. high loss-
to-follow-up, low external validity) [1, 2]. The widespread
availability of new technologies has the potential of shift-
ing some research activities, including enrollment, man-
aging trial activity, reporting results, and safety oversight,
away from study sites. Such “remote” research may en-
courage the participation of a more diverse group of pa-
tients in research with improved recruitment rates and at
lower costs than those of conventional trials [3–5]. A
combinatory approach including direct interactions with
the study team may allow remote data collection to be op-
timally leveraged [6, 7], e.g. by addressing challenges
around data quality and retention [8–11].
In pediatric care, empirical evidence on the optimal dos-
ing and action of routinely used medicine remains limited
[12–14]. The relationship between drug exposure and its
effects are often different in children compared to adults.
For this reason a simple extrapolation of pediatric dosing
based on adult data can put children at increased risk of
adverse events and therapeutic failures [15–17]. Therefore,
innovative clinical study designs in pediatrics are urgently
needed. Currently, major challenges of designing and con-
ducting clinical trials in children, include (i) small sample
sizes of pediatric studies, (ii) increased study complexity
due to multiple age groups, (iii) integration of research in
daily activities of the whole family affecting parental time
of work and supervision of other children, and (iv) child
absence of routine activities. Together with the burdens of
travel and frequent site visits, these limits are associated
with low recruitment and high dropout rates [18, 19].
Recent “care-at-home”-initiatives indicate that mobile
or remote approaches in clinical research with children
have the potential to increase patient and caregiver satis-
faction without increasing privately borne costs [20]. In
addition, today’s parents and their children are technol-
ogy savvy and frequent users of mobile devices, suggest-
ing their high potential as future candidates in remote
clinical trials. While the methodology is still in its in-
fancy, increasing interest and support from regulators,
sponsors, and patients will likely propel remote trials
forward in the near future [21]. Thus, further investiga-
tion into the methodology of studies that use a combin-
atory approach is warranted. In this pilot study, we
aimed to investigate the feasibility of remotely collecting
valid (i.e. complete and correct) clinical data and saliva
samples in a pediatric population utilizing mobile tech-
nologies. In addition, we assessed the general accept-
ance, reasons for non-consent, and the resulting costs of
this study.
Methods
Study design
This was an investigator-initiated, single center, pro-
spective pilot study investigating the feasibility of re-
motely conducting clinical studies with parents/legal
representatives (“caregivers”) and children. We devel-
oped a custom mobile application (“app”) allowing pa-
tients and their caregivers to participate in the study
remotely after an initial training session at our institu-
tion (details of application development may be found in
Additional file 1). We elected pain management after
tonsillectomy as a model due to the frequency of the
surgical procedure in children younger than 15 years
[22] requiring standardized analgesic therapy and the
potential to remotely assess pain levels by caregivers
using a validated scale (The Childhood Discomfort and
Pain Scale) [23]. In addition, remotely collect saliva sam-
ples were planned to measure acetaminophen concentra-
tions mimicking the design of a pharmacokinetic (PK)
study. In addition, the local standard of care sequence
after tonsillectomy consisting of two to four days in-
patient care after surgery allowed study staff to train
caregivers in the use of study technologies and proce-
dures for the at-home phase.
Total study duration for each participant and care-
givers was 10 days during which data and samples were
collected on 2–4 days as an inpatient and on 3 days at
home. On day 8, the caregivers filled out a feasibility
questionnaire. On day 10, study staff additionally con-
tacted caregivers for feedback on the study in a follow-
up telephone interview.
Participant eligibility
Children presenting for elective tonsillectomy were
screened and enrolled at the University of Basel Chil-
dren’s Hospital from May 26 2016 until January 07 2017,
during the pre-surgery anesthetics consultation. Inclu-
sion criteria were age between 2 and 10 years, routine
elective tonsillectomy (with or without other additional
Ear, Nose, and Throat intervention), anticipated in-
patient stay of a minimum of 2 days, willingness and
ability of caregivers to understand and implement study
procedures in the hospital and at home, and ability of
caregivers to understand, speak, and read German. Ex-
clusion criteria were contraindications to acetaminophen
administration and any reasons precluding the collection
of saliva samples.
Study procedures
Screening of eligible patients was performed at the pre-
anaesthetics clinic consultation by a physician and a
study nurse. After assessment of inclusion/ exclusion
criteria and written informed consent, the study nurse
informed caregivers about the mobile study application,
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provided them with an instruction manual, and sup-
ported them in the setup of their login. Caregivers had
the possibility to choose between their own mobile
phone (Bring Your Own Device, “BYOD”), or an iPod-
Touch provided by the study team for the duration of
the study.
On the day of tonsillectomy, a study nurse explained
the procedures, data collection and the Childhood Dis-
comfort and Pain Scale to participating children and
caregivers. After the surgeon performed tonsillectomy,
postoperative pain management with acetaminophen
was initiated according to the current standard of care
of the hospital [24]. The study did not interfere with
routine pain management. Participating children stayed
on the ward for approximately 3 days (Fig. 1).
Daily data and sample collection was scheduled to
mimic a pharmacokinetics- and dynamics (PK/PD)
study. The mobile app issued automatic electronic re-
minders for scheduled doses as well as pain assessment/
sample collection time points. Data entry was automatic-
ally time stamped. Pain assessment was repeated 3 times
a day by the caregivers upon awakening of the partici-
pating children in the morning (tM) and 1 (+/− 15 min,
t1) and 4 (+2 h, t2) hours after administration of the first
routinely scheduled dose of acetaminophen. Saliva sam-
ples were collected twice daily for each participant at t1
and t2. Sample codes were either scanned using the
mobile application scanning function or typed in by
caregivers. All concomitant medication allowed accord-
ing to the guidelines of the hospital was documented
throughout the study by taking a photograph of the
blister or package using the mobile application. After
initial supervision by a study nurse, caregivers conducted
these assessments autonomously while still in the
inpatient setting.
On day 3(+/− 1 day) post-surgery, participating chil-
dren were discharged home. The study nurse explained
how to collect and store saliva samples at home and pro-
vided labeled containers for all samples. Children staying
in hospital longer than 4 days were excluded from the
study. On the 3 days following discharge, caregivers col-
lected data and samples at home following the scheme
established during the inpatient stay. On study day 8, a
bicycle messenger collected all saliva samples. The mo-
bile application reminded caregivers to fill in a feasibility
questionnaire before uploading data to the study server.
On day 10, a study nurse conducted a follow-up
telephone call for general caregiver feedback.
Statistical analyses
Primary and secondary endpoints
The primary endpoint of the study was the propor-
tion of simultaneously complete and correct data (pain
scale or saliva) in the at-home setting. A complete
data set consisted of five data points (three pain scale
assessments and two saliva samples) for each day and
patient. Complete pain scale data were considered
correct if collected within the predefined timeframes
(1 h (+/− 15 min) and 4 h (+2 h) after first medica-
tion). Complete saliva samples were considered cor-
rect if i) collected within predefined timeframe, ii)
saliva volume sufficient for potential laboratory ana-
lyses, and iii) unique sample ID entered into mobile
application. In the initial analysis plan, we aimed to
measure acetaminophen levels which were omitted
due to technical limitations in reliably detecting acet-
aminophen in saliva. Secondary endpoints included
the proportion of complete and correct samples in
the inpatient setting (training setting before hospital
release, collected as described for the out-patient
Fig. 1 Daily data collection schedule. tM: Timepoint directly after awakening of child, t1: 1 h (+/− 15 min) after administration of first routinely
scheduled dose of acetaminophen; t2: 4 h (+2 h) after administration of first routinely scheduled dose of acetaminophen. * “Medication given”
indicates the timepoint at which children had either received routine acetaminophen, or not (yes/no). Independent of whether medication was
given or not, the app used the recorded time stamp to automatically calculate t1 and t2
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setting), the subjective feasibility for caregivers as mea-
sured by an electronic questionnaire on day 8, the
percentage of consenting patients, the reasons for non-
consent, the legibility of photos of concomitant medica-
tion using the mobile application, and study cost.
Primary analysis
The full analysis set consisted of all patients and care-
givers who fulfilled all inclusion criteria and consented
to take part. We descriptively summarized the propor-
tion of complete and correct clinical data (pain scale)
and samples (saliva) collected in the at home setting. In
addition, the number of complete and correct samples
per patient was modeled in a logistic regression and the
95% confidence interval (CI) was estimated based on
profiled log-likelihood functions. Based on our experi-
ence with paper-based patient-reported outcomes (e.g.
questionnaires), our hypothesis was that the overall
completeness and correctness of electronically collected
data would be above a predefined threshold of 90%.
Secondary analyses
The proportion of simultaneously complete and correct
data (pain scale or saliva) in the inpatient setting was an-
alyzed as described for the primary endpoint. In
addition, both analyses were repeated with a secondary
analysis set consisting of 15 patients who used the new-
est version of the mobile application. Baseline character-
istics, study flow statistics, reasons for non-consent,
feasibility questionnaires, and legibility of images were
summarized and presented descriptively.
Missing data and drop-outs
Missing data were part of the primary endpoint
(completeness not reached). Patients who were re-
hospitalized within three days after discharge were con-
sidered drop-outs, and reasons were documented. All
other data were assumed to be missing at random and
no imputations were performed.
Cost analysis
We describe a total study cost approach factoring in app
development and testing, on-site, data management,
analysis staff time, study-specific materials, laboratory
sample analysis, and transport costs. Cost calculations
were based on salaried staff time log sheets and fixed
costs for materials. Sensitivity analyses include cost for a
traditional, fully on-site conducted scenario, and cost for
larger samples size studies.
Results
Patient and caregiver characteristics
Of the 45 patients and their caregivers assessed for eligi-
bility, twenty-three (51.1%) were enrolled in the study,
and 17 (37.8%) completed the full study (Fig. 2). Of the
15 (33.3%) caregivers who declined to participate, thir-
teen consented to provide a reason for non-consent,
which predominantly included the perceived time bur-
den of the study (8/13, 61.5%) (Table 1). Of 23 enrolled
patients, 6 (26%) dropped out during study conduct.
Reasons included one non study-related serious adverse
event, patient refusal to provide saliva samples, technical
issues with the mobile application, and contraindications
to acetaminophen (Fig. 2).
Baseline characteristics of the 17 patients and care-
givers who completed the study are described in Table 2.
Median age of patients and caregivers was 6.0 (Inter-
quartile Range (IQR) 5.0–7.4) and 35.0 (IQR 32.0–38.0),
respectively. A majority of patients (11/17, 64.7%) had
one sibling, and 14/17 caregivers (82.4%) were native
German speakers.
Completeness and correctness of saliva sampling and
pain assessments at home
In total, caregivers collected 303 pain scale assessments
and 202 saliva samples. During the at-home phase,
71.9% [CI = 64.4, 78.6] of all pain assessments were
complete and correct (92.2% complete, and thereof
78.0% correct) compared to 53.9% [CI = 44.2, 63.4]
(77.5% complete, and thereof 69.6% correct) of all saliva
samples (Table 3). Overall, 64.7% [CI = 58.7, 70.4] of all
data collected by caregivers at home was complete and
correct.
Fig. 2 TOMACHI Study Flow Diagram
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Completeness and correctness of saliva sampling and
pain assessments in the inpatient setting
In the inpatient setting, 62.0% of all pain measurements
were complete and correct ([CI = 54.1, 69.5], 94.0%
complete and thereof 66.0% correct, respectively) com-
pared to 39.0% ([CI = 29.8, 48.7], 77.0% complete, and
thereof 50.6% correct, respectively) of saliva samples. Over-
all, 52.8% [CI = 46.6, 58.9] of all data collected by care-
givers in the inpatient setting was complete and correct.
Reasons for incompleteness and incorrectness and
exploratory sensitivity analyses
Incompleteness of data was mostly due to technical is-
sues which two caregivers experienced (predominantly
affecting saliva samples) or the discontinuation of data
collection by one caregiver at home. Exploratory ana-
lyses of the subgroup of participants who did not experi-
ence technical issues with an early version of the mobile
application (n = 15) showed that completeness and
correctness of pain assessments remained the same
(71.9%), but that the percentage of correct and complete
saliva samples increased from 53.9% to 61.1%. The rea-
son for this was a programming issue, which affected the
entry of saliva sample IDs in the application.
The major reason for incorrectness of data was incor-
rect timing (i.e. data was not collected within predefined
timeframes of 1 h (+/−15 min), and four hours (+2 h)
after first medication, in Additional file 2: Table S1). Ex-
ploratory sensitivity analyses assuming that all data had
to be collected within one calendar day instead of the
narrow timeframes of 1 and 4 h showed that in this case
92.2% of pain scale data and 74.5% of saliva samples
would have been complete and correct at home, and
94.0% and 73.0% in the inpatient setting, respectively
(Additional file 2: Table S2). Further, a positive trend for
complete and correct data and sample collection was ob-
servable from day one in the inpatient setting to day three,
i.e. the day of hospital release. On the first day at home,
the proportion of complete and correct data increased
once more, before then declined slightly (Additional file 3:
Figure S1). No clear trend in the quality of data collection
could be identified regarding the individual patient and
caregiver (Additional file 4: Figure S2), or when stratifying
the analysis by number of siblings, caregiver occupation,
or caregiver native language.
Legibility of concomitant medication images
Of the 17 patients who completed the study, 10 (58.8%)
took 24 different images of medications using the mobile
application’s imaging function. All 24 images were sharp
and legible. Medication names were identifiable on 18
(75%) and dosage information (e.g. on drug containers,
blisters, etc.) on 13 (54.2%) of all 24 images, respectively.
Table 1 Reasons for caregiver non-consent
n (%)
Caregivers who declined to participate (n = 15)
and provided reason for non-consent
13 (86.7)
I do not have the time to conduct the study 8 (61.5)
I do not believe I can collect data and samples correctly 4 (30.8)
I do not want to put additional burden on my child 3 (23.1)
I did not fully understand what the study is about 2 (15.4)
I generally have doubts about clinical research 0 (0)
I would be interested to participate in such a
study in the future
6 (46.2)
Table 2 Baseline characteristics of patients and caregivers
n (%) 17 (100)
Patient gender (n male (%)) 10 (58.8)
Age (median years [IQR]) 6.0 [5.0, 7.4]
Number of siblings (%)
0 2 (11.8)
1 11 (64.7)
2 2 (11.8)
3 2 (11.8)
Caregiver age (median years [IQR]) 35.0 [32.0, 38.0]
Caregiver native German speaker = yes (%) 14 (82.4)
Caregiver working at the moment = yes (%) 12 (70.6)
Caregiver occupation (ISCO) (%)
At home/unemployed 5 (29.4)
Professional 3 (17.6)
Service and sales workers 9 (52.9)
Caregiver volume of work (median weekly % [IQR]) 60.0 [40.0, 70.0]
IQR Interquartile Range, ISCO International Standard Classification
of Occupations
Table 3 Completeness and correctness of caregiver collected
data and samples
Complete and correct
No Yes
Location Item Total n n % n %
At home Pain scale 153 43 28.1 110 71.9
Saliva samples 102 47 46.1 55 53.9
All 255 90 35.3 165 64.7
Inpatient Pain scale 150 57 38.0 93 62.0
Saliva samples 100 61 61.0 39 39.0
All 250 118 47.2 132 52.8
All Pain scale 303 100 33.0 203 67.0
Saliva samples 202 108 53.5 94 46.5
All 505 208 41.2 297 58.8
von Niederhäusern et al. BMC Medical Research Methodology  (2017) 17:163 Page 5 of 9
Feasibility and practicability for caregivers
Out of 17 caregivers, 15 provided answers in the feasibil-
ity questionnaire. Nine of 15 (60.0%) caregivers thought
studies at home are a good idea and 53.3% (8/15) would
probably take part again (Additional file 2: Table S3).
Over 66% (10/15) of caregivers spent less than 15 min
on study procedures. In 73.3% (11/15), the mother was
the primary caregiver collecting data and samples for the
study at home. 60% (9/15) of caregivers said that study
goals were explained “very well” to them in the begin-
ning, compared to 53% (8/15) who said study procedures
were explained “well”. Usability of the study app was
rated between “ok” (8/15, 53.3%) and “great” (6/15,
40.0%). 66.7% (10/15) rated the study procedures “easy”
in the inpatient setting compared to 40.0% (6/15) in the
at home setting. Asking caregivers about potential diffi-
culties, 86.6% (13/15) answered that the study flow, i.e.
the timing of data and sample collection, was sometimes
difficult to follow (Additional file 2: Table S4).
Study cost and cost comparison
Total study cost included fixed costs ($44′577) such as
application development and support ($11′955), study-
specific materials (two iPods, saliva sampling tubes,
envelopes, cafeteria vouchers for caregivers, $2′507),
laboratory sample analysis ($2′224), study-material
transport costs from caregiver’s home at the end of the
study ($474), database setup, management and statistical
analysis ($21′360), study monitoring ($6′057) and vari-
able salaried on site staff cost (part time; one physician,
three study nurses) over the eight months the study was
active ($ 19′157), summing to a total of $63′734 and $3′
749 per patient who completed the study.
Our sensitivity analyses for a traditional, hospital-based
approach for the same study with the same duration, but
six full study days in the inpatient setting and data collec-
tion by study nurses suggested total fixed costs of $35′593
compared with $44′577 for the pilot study, and variable
on-site staff costs of $20′202 compared with $19′157 for
the mobile study summing to a total of $55′795 and $3′
281 per patient. The difference was driven by the high ini-
tial cost for app development and support, but lower study
nursing, physician, and data entry time compared to a
traditional trial. Increasing the sample size from 17 to
hypothetical 100 evaluable patients would have resulted in
cost per patient of $1′077 for the mobile trial and $1′307
for the hospital-based approach.
Discussion
Results from our pilot study indicate that mobile data
and sample collection for clinical studies with children
and their caregivers are feasible, yet subject to certain
caveats. We were able to engage and enrol patients and
to conduct the study with retention rates comparable to
those of studies done in traditional settings. Further-
more, the participating caregivers reported high levels of
satisfaction and willingness to participate in similar trials
in the future. However, the overall proportion of
complete and correct data collected in the current
framework would not be sufficient to obtain valid study
results for a stand-alone PK study. However, sparse PK
data collected in such at-home study may be combined
with data from more conventional PK studies to enhance
PK/PD analyses including pharmacometric modelling.
While 92.2% of pain scale data and 77.5% of samples were
complete, only 78.0% and 69.6% thereof were correct, re-
spectively. We could therefore not prove our hypothesis
of 90% complete and correct data and sample collection
in the at home setting. Reasons for this included the nar-
row timeframe in which data and samples had to be col-
lected by caregivers, the handling of saliva samples, and
technical issues with the application.
Expanding the narrow timeframes to one full calendar
day, however, would have resulted in over 92% of pain
measurements to be complete and correct in the at
home setting. We therefore believe that other study
types such as phase III or IV studies or observational re-
search with less time-critical data to be collected may be
viable options to make use of mobile data collection.
Examples may include postoperative observations, the
assessment of quality of life outcomes, medication
management in chronic conditions or continuous
physiological measures using sensor devices.
Exploratory analysis of factors such as number of sib-
lings, caregiver occupation, or caregiver native language
did not reveal any clear trend in supporting complete
and correct data collection among caregivers. As ex-
pected, this pilot study did not yet prove cost-effective
due to the development cost of the application. How-
ever, future studies including larger samples sizes and
building on an improved framework of the existing ap-
plication will be a cost-efficient option.
Although our participants seemed broadly similar to
those in comparable traditional trials, the requirement
for ease in mobile phone handling (in our pilot restricted
to iPhone and iPods), understanding of the German lan-
guage, and the active choice by caregivers to conduct
the study at home probably may have resulted in selec-
tion bias. While this study planned to leverage study
participants’ own Internet-enabled mobile devices for re-
mote data collection (“Bring Your Own Device”), we also
provided study mobile devices in order to avoid add-
itional caregiver selection bias. External validity is also a
common problem for traditional trials, and adequate de-
scription of the setting and the sample characteristics is
needed. In future mobile trials, we therefore aim to ex-
tend the pilot setting to different mobile technologies
(i.e. Android) and multiple languages.
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Furthermore, the mobile application was designed with
the highest user flexibility and –usability in mind in
order to minimize user fatigue or dropout. This flexibil-
ity in data entry resulted in data points which were often
ambiguous (e.g. inconsistencies in automatic time stamp
versus time point indicated by caregiver, or typing errors
for sample codes). We decided to strictly analyse the
data as transmitted by the caregivers although some of
these data point ambiguities could have been resolved by
the investigators by applying logical cross-checks.
While this pilot was efficient with respect to direct
caregiver-reported data entry and on-site staffing levels,
data management and analysis of the app-collected data
structure was more resource intense than expected. Par-
ticular hurdles were (i) the translation of structured data
recorded by the mobile application (json-format) into a
tabular format suitable for statistical analysis and (ii) to
incorporate the flexibility given to the users for data
entry. For future studies, translation of structured data
can be easily optimized by establishing standardized pro-
cedures, whereas specific care must be taken to reduce
flexibility in data entry to avoid a high degree of com-
plexity in data analysis.
According to the US Food and Drug Administration,
electronic capture of clinical trial source data is
nowadays preferred over paper-based data collection
[21, 25]. However, data quality has been reported to be
problematic [8, 9], and combinations of mobile tech-
nologies with appropriate interactive guidance by study
staff were suggested to be more successful [3, 4]. To
our knowledge, this is the first study explicitly evaluat-
ing the quality of data resulting from mobile data cap-
ture in a setting imitating pediatric PK/PD modelling.
We combined an initial caregiver training session in the
inpatient setting including the possibility to interact with
study staff with an independent at-home phase. Caregivers
were satisfied with study staff support in the inpatient set-
ting, but reported more difficulties following the study
procedures at home (Additional file 2: Table S3).
As described by Murray [9] and Coons [25], there are
generally two concerns about data quality in clinical stud-
ies: Validity – to what extent is the information provided
by participants is “true”- and amount of missing data, in
terms of item nonresponse. While missing data is gener-
ally expected to be minimized with automatic reminders
issued by electronic applications, patient-reported data
validity may be problematic in both mobile and traditional
on paper studies. In this study, we confirm that missing
data is less of an issue than data validity. If we had allowed
caregivers to collect data and samples within one calendar
day rather than within narrow timeframes, 92.2% of all
pain measurements and 74.5% of saliva samples would
have been complete and correct in the at home setting
(Additional file 2: Table S2).
Further, self-reported patient outcomes have gener-
ally been criticized before with respect to internal
validity and data quality, but are often necessary to
adequately evaluate the treatment benefit provided by
new interventions [25]. We used a standardised scale
for pain assessment [23] by caregivers as a model for
mobile data collection. Automatic time stamps for
data entry aimed to improve data validity (e.g. cor-
rect timing), and allowed the study team to better
judge the validity of patient-reported measurements
compared to paper based data. In future versions of
the application, all patient-reported assessments will
therefore be validated for computer use if possible,
and methods for case confirmations by study staff
will be included to be able to judge the validity of
data points.
A recent survey [10] across pharmaceutical compan-
ies revealed that just 37% are currently using mobile
technologies in clinical trials, of which more than two-
thirds (68%) are mobile apps. The primary benefit that
companies see for adopting “mHealth” technologies is
real-time data acquisition (36%), followed closely by
increased patient compliance (30%) and improved data
quality (25%). The first successfully completed fully
remote Diabetes management trial, the VERKKO trial,
sponsored by Sanofi reported initial results on high
patient satisfaction rates, reduced study coordination
activities, faster study completion, and increased
patient retention rates [26]. Nevertheless, companies
still have a number of concerns around the technology.
Data security is the primary concern for almost a third
of respondents (32%), whilst difficulty in incorporation
(29%) and resistance from patients or physicians (23%)
are both considerable worries. While we did not
experience any of these, our study revealed that data
quality may only be improved if the mobile application
is supporting data collection that is a) well-structured
and easy to follow for patients, b) flexible to some
extent (i.e. large timeframes), but still rigid enough to
assure resulting data quality (i.e. using automatic time
stamps rather than patient-reported time points which
are prone to error), and ideally, c) remotely monitored.
Compared to traditional on paper study settings, users
of mobile technologies for clinical studies should make
use of their potential of real-life data monitoring and
automatic time stamps that should ultimately improve
overall patient-reported data validity.
Due to the particular scientific and technological
issues associated with the use of mobile devices that
currently inhibit their widespread use, the Clinical
Trials Transformation Initiative (CTTI) is developing
recommendations for managing mobile devices in
clinical trials, and guiding principles to promote their
inclusion [11].
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Conclusion
In conclusion, mobile studies conducted at home are a
feasible approach when certain circumstances are met.
Future electronic at-home data collection should pre-
dominantly include data that is not time critical at pre-
defined, yet flexible time points. Further, the collection,
storage, and shipping of biological samples have proven
more difficult and should be kept at a minimum. There-
fore, we would refrain from conducting remote “stand
alone PK studies” that require a rigid data and samples
collection schedule. However, studies with more flexible
data acquisition schedules, such as clinical phase III or
IV trials with sparse PK and biomarker sampling, and
observational studies could profit from such an ap-
proach. Importantly, mobile applications need to be de-
signed in a well-balanced manner, allowing for user
flexibility but also assuring resulting data quality.
Current efforts at the CTTI specifically target the tech-
nical and scientific issues that still remain with mobile
devices in clinical research. In the future, we expect an
enhanced version of our current technology to reach
wider patient populations and to incorporate lessons
learned with features such as remote patient monitoring
using real life data capture and increased site-patient
interaction.
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